| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/20/2013 | US20130158234 Specific binding agents of human angiopoietin-2 |
| 06/20/2013 | US20130158232 Method for selecting a candidate drug compound |
| 06/20/2013 | US20130158103 Method of Tissue-Selective Targeted Gene Transfer |
| 06/20/2013 | US20130157965 Prevention and Treatment of Oxidative Stress Disorders by Glutathione and Phase II Detoxification Enzymes |
| 06/20/2013 | US20130157964 Blockade Of Inflammatory Proteases With Cyclic Peptides |
| 06/20/2013 | US20130157962 Methods for inhibiting growth of prolactin-responsive cancer cells with cyclosporine a or other cyclophilin inhibitors |
| 06/20/2013 | US20130157961 Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use |
| 06/20/2013 | US20130157960 Novel auristatin derivatives and use thereof |
| 06/20/2013 | US20130157959 Use of hades as tumor suppressor target |
| 06/20/2013 | US20130157955 Method of drug delivery for bone anabolic protein |
| 06/20/2013 | US20130157954 Methods for treatment or prophylaxis of kidney or liver dysfunction |
| 06/20/2013 | US20130157951 Pharmaceutical Composition Containing Goserelin for In-Situ Implant |
| 06/20/2013 | US20130157950 Method for treating and/or preventing neurodegenerative disease by adiponectin receptor agonist |
| 06/20/2013 | US20130157949 Novel Peptides for Wound Healing |
| 06/20/2013 | US20130157947 Compounds for stem cell differentiation |
| 06/20/2013 | US20130157945 Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof |
| 06/20/2013 | US20130157944 Treatment of Myocardial Infarction and Vascular Injury with Netrin-1 |
| 06/20/2013 | US20130157943 Method and use of peptide antagonists of zonolin to prevent or delay the onset of diabetes |
| 06/20/2013 | US20130157936 Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin |
| 06/20/2013 | US20130157935 Glucagon analogues |
| 06/20/2013 | US20130157932 Ngal and urinary tract infection |
| 06/20/2013 | US20130157929 Glucagon analogues |
| 06/20/2013 | US20130157928 Nociceptin mimetics |
| 06/20/2013 | US20130157925 Compositions and methods for the treatment of cancer |
| 06/20/2013 | US20130156850 Apo a-i mimetic peptides and methods of treatment |
| 06/20/2013 | US20130156849 Modified nucleoside, nucleotide, and nucleic acid compositions |
| 06/20/2013 | US20130156801 Compositions and methods for exosome targeted expression |
| 06/20/2013 | US20130156798 Peptide composition |
| 06/20/2013 | US20130156795 Methods for inhibition of cell proliferation, synergistic transcription modules and uses thereof |
| 06/20/2013 | US20130156793 Insulin-resistance-improving drug |
| 06/20/2013 | US20130156792 Uniform field magnetization and targeting of therapeutic formulations |
| 06/20/2013 | US20130156791 Methods and pharmaceutical compositions for the treatment of hiv-1 infections |
| 06/20/2013 | US20130156785 Novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases |
| 06/20/2013 | US20130156776 Compositions and methods for treating cancer and modulating stress granule formation |
| 06/20/2013 | US20130156775 Chlamydia trachomatis antigens |
| 06/20/2013 | US20130156766 Treatment of dry age related macular degeneration |
| 06/20/2013 | US20130156764 Neutralization of flt3 ligand as a leukemia therapy |
| 06/20/2013 | US20130156763 ILT3 Polypeptides and Uses Thereof |
| 06/20/2013 | US20130156756 Substituted Triazolopyridines |
| 06/20/2013 | US20130156753 THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
| 06/20/2013 | US20130156750 Compositions and Methods for Using Human YKL-40 to Treat Acute Lung Injury |
| 06/20/2013 | US20130156749 Pretreatment or post exposure treatment for exposure to a toxic substance by pulmonary delivery (inhaler) of a bioscavenger |
| 06/20/2013 | US20130156745 Composition for enzymatic debridement |
| 06/20/2013 | US20130156737 Secretion System and Methods for its Use |
| 06/20/2013 | US20130156735 Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis |
| 06/20/2013 | US20130156734 Compositions and Methods for Treating Friedreich's Ataxia with Interferon Gamma |
| 06/20/2013 | US20130156733 Influenza virus populations, methods of use and methods of making thereof |
| 06/20/2013 | US20130156730 Neoadjuvant treatment of cancer with proleukin |
| 06/20/2013 | US20130156729 Mammalian Receptor Proteins; Related Reagents and Methods |
| 06/20/2013 | US20130156726 Endometrial stem cells and methods of making and using same |
| 06/20/2013 | US20130156713 Compositions for enhancing nail health |
| 06/20/2013 | US20130156704 Therapy for subarachnoid hemorrhage and ischemia |
| 06/20/2013 | US20130156703 Methods, Compounds, and Compositions For Treatment and Prophylaxis in the Respiratory Tract |
| 06/20/2013 | US20130156702 Methods for the treatment and the diagnosis of cancer |
| 06/20/2013 | US20130156696 Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse |
| 06/20/2013 | US20130156695 Use of zcytor17 ligand antagonists for treating inflammatory diseases |
| 06/20/2013 | US20130156691 Antibody Therapy |
| 06/20/2013 | CA2858276A1 Pharmaceutical formulations and the use thereof for the treatment of peanut allergy |
| 06/20/2013 | CA2858253A1 Human insulin analogue and acylated derivative thereof |
| 06/20/2013 | CA2857276A1 Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin |
| 06/20/2013 | CA2857197A1 Novel glp-1 receptor modulators |
| 06/20/2013 | CA2855574A1 Inhibitors of hcv ns5a |
| 06/20/2013 | CA2853204A1 Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases |
| 06/19/2013 | EP2605013A1 Stimulation of pancreatic beta-cell proliferation |
| 06/19/2013 | EP2604693A2 TNFSF single chain molecules |
| 06/19/2013 | EP2604692A1 Immunology treatment for biofilms |
| 06/19/2013 | EP2604689A1 Anti-obesity agent and anti-obesity food |
| 06/19/2013 | EP2604623A2 Transferrin variants and conjugates |
| 06/19/2013 | EP2604281A1 Clicked somatostatin conjugated analogs for biological applications |
| 06/19/2013 | EP2604275A1 Use of Recombinant LAG-3 or the Derivatives Thereof for Eliciting Monocyte Immune Response |
| 06/19/2013 | EP2604264A1 Pharmaceutical composition for treating viral diseases |
| 06/19/2013 | EP2603587A1 Methods and pharmaceutical compositions for the treatment of hiv-1 infections |
| 06/19/2013 | EP2603520A2 Erythrocyte-binding therapeutics |
| 06/19/2013 | EP2603232A2 Stable formulations of linaclotide |
| 06/19/2013 | EP2603231A2 Environmentally sensitive compositions |
| 06/19/2013 | EP2603228A1 Use of angiotensin- ii (1-7) in cell transplantation and as an agent for preventing/treating norovirus infection |
| 06/19/2013 | EP2603227A2 Improved hematopoietic stem and progenitor cell therapy |
| 06/19/2013 | EP2603226A2 Treatment of diabetes with pancreatic endocrine precursor cells |
| 06/19/2013 | EP2603221A2 Ggf2 and methods of use |
| 06/19/2013 | EP2603220A1 Antisense antiviral compounds and methods for treating a filovirus infection |
| 06/19/2013 | EP2603204A2 Formulations for infusion of type b lantibiotics |
| 06/19/2013 | CN103168029A Salts and polymorphs of sulfamide ns3 inhibitors |
| 06/19/2013 | CN103167878A Treating diabetes melitus using insulin injections administered with varying injection intervals |
| 06/19/2013 | CN103167877A Composition comprising glutathione reductase and oxidized glutathione, and therapeutic uses thereof |
| 06/19/2013 | CN103167876A Improved hematopoietic stem and progenitor cell therapy |
| 06/19/2013 | CN103160569A Discovery for new mechanism for regulating dynamic state of cell microfilaments |
| 06/19/2013 | CN103160558A Method for preparing lactalbumin hydrolysate |
| 06/19/2013 | CN103160557A Purpose of ribosomal protein S5 in catalyzing of protein molecules for generatation of dephosphorylation reaction |
| 06/19/2013 | CN103160555A Culture medium, culture method and application of high-yield exotoxin of clostridium perfringens |
| 06/19/2013 | CN103160531A NGR-VEGI fusion protein as well as encoding gene and expression and purification method thereof |
| 06/19/2013 | CN103160526A Mytilus edulis G-type lysozyme gene and recombinant protein and application thereof |
| 06/19/2013 | CN103160525A Mytilus edulis G-type lysozyme gene and recombinant protein and application thereof |
| 06/19/2013 | CN103160488A Antarctic ice algae CPD photolyase, and coding gene, expression vector and application thereof |
| 06/19/2013 | CN103160485A Agkistrodon acutus hemocoagulase-C |
| 06/19/2013 | CN103159860A Recombinant tissue-type plasminogen activator, and preparation method and use thereof |
| 06/19/2013 | CN103159851A Micromolecule polypeptide preventing and restraining inflammation and application thereof |
| 06/19/2013 | CN103159848A Two series major vault protein of glucagon-like peptide-2 of people and preparation method thereof |
| 06/19/2013 | CN103159847A Natriuretic peptide, as well as gene and use thereof |
| 06/19/2013 | CN103159844A Method capable of reducing immunotoxicity of venom nerve growth factor and enabling immunotoxicity to be drug alternative of mouse origin nerve growth factor |
| 06/19/2013 | CN103159843A Preparation method and drug application value of nerve growth factor mutant with low immunization side effects |